Annemarie Forrest

Mrs. Annemarie Forrest


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2019 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Open access
PDF file
MAMaria Apostolaros
Maria Apostolaros
DBDavid Babaian
David Babaian
ACAmy Corneli
Amy Corneli
AFAnnemarie Forrest
Annemarie Forrest
GHGerrit Hamre
Gerrit Hamre
PRPenny Randall
Penny Randall
Background Traditional clinical trials are often expensive, inefficient, include selected populations, and can create significant participant burden via travel and other logistical demands. Using new technologies and methodologies to promote a decentralized approach has the potential to improve the efficiency of clinical trials. The Clinical Trials Transformation Initiative (CTTI)—a public–private partnership to improve clinical trials—launched a multi-stakeholder Decentralized Clinical Trials (DCTs) Project to provide recommendations on addressing the actual and perceived legal, regulatory, and practical challenges with DCT design and conduct in the United States. Methods Informed by qualitative group interviews and an expert meeting, CTTI engaged stakeholders to identify key challenges to implementing DCTs and possible solutions. Results The CTTI DCT project team used the interview findings and expert feedback to develop recommendations that will drive broader use of DCTs. Conclusions CTTI’s recommendations cover protocol design, use of telemedicine and mobile healthcare providers, medical product supply chain, investigator delegation and oversight, and safety monitoring considerations. By implementing these recommendations, sponsors, contract research organizations, and others can help advance successful medical product development using mobile technologies and methodologies in DCTs.

6 November 2019 in Digital Biomarkers
Verified
Journal Article
Open access
PDF file
PCPhilip Coran
Philip Coran
JGJennifer C. Goldsack
Jennifer C. Goldsack
CGCheryl A. Grandinetti
Cheryl A. Grandinetti
JBJessie P. Bakker
Jessie P. Bakker
MBMarisa Bolognese
Marisa Bolognese
ADAiden Doherty
Aiden Doherty
Mobile technologies offer the potential to reduce the costs of conducting clinical trials by collecting high-quality information on health outcomes in real-world settings that are relevant to patients and clinicians. However, widespread use of mobile technologies in clinical trials has been impeded by their perceived challenges. To advance solutions to these challenges, the Clinical Trials Transformation Initiative (CTTI) has issued best practices and realistic approaches that clinical trial sponsors can now use. These include CTTI recommendations on technology selection; data collection, analysis, and interpretation; data management; protocol design and execution; and US Food and Drug Administration submission and inspection. The scientific principles underpinning the clinical trials enterprise continue to apply to studies using mobile technologies. These recommendations provide a framework for including mobile technologies in clinical trials that can lead to more efficient assessment of new therapies for patients.

6 June 2019 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
JBJessie P. Bakker
Jessie P. Bakker
JGJennifer C. Goldsack
Jennifer C. Goldsack
MCMichael Clarke
Michael Clarke
ACAndrea Coravos
Andrea Coravos
CGCynthia Geoghegan
Cynthia Geoghegan
WWWilliam A. Wood
William A. Wood
Mobile technologies, such as smart phone applications, wearables, ingestibles, and implantables, are increasingly used in clinical research to capture study endpoints. On behalf of the Clinical Trials Transformation Initiative, we aimed to conduct a systematic scoping review and compile a database summarizing pilot studies addressing mobile technology sensor performance, algorithm development, software performance, and/or operational feasibility, in order to provide a resource for guiding decisions about which technology is most suitable for a particular trial. Our systematic search identified 275 publications meeting inclusion criteria. From these papers, we extracted data including the medical condition, concept of interest captured by the mobile technology, outcomes captured by the digital measurement, and details regarding the sensors, algorithms, and study sample. Sixty-seven percent of the technologies identified were wearable sensors, with the remainder including tablets, smartphones, implanted sensors, and cameras. We noted substantial variability in terms of reporting completeness and terminology used. The data have been compiled into an online database maintained by the Clinical Trials Transformation Initiative that can be filtered and searched electronically, enabling a user to find information most relevant to their work. Our long-term goal is to maintain and update the online database, in order to promote standardization of methods and reporting, encourage collaboration, and avoid redundant studies, thereby contributing to the design and implementation of efficient, high-quality trials.

1 February 2020 in Contemporary Clinical Trials
Verified
Journal Article
Open access
JBJimmy Bechtel
Jimmy Bechtel
TCTina Chuck
Tina Chuck
AFAnnemarie Forrest
Annemarie Forrest
CHChristine Hildebrand
Christine Hildebrand
JPJanette Panhuis
Janette Panhuis
TSTeresa Swezey
Teresa Swezey
The Clinical Trials Transformation Initiative (CTTI) Investigator Qualification Project addresses the need for a more efficient and effective means of identifying qualified clinical investigators and delegates. Selection of investigators and delegates who are qualified by training and experience to conduct clinical trials is essential to safeguarding protections for study participants and ensuring data quality and integrity. Sponsors generally document investigator qualification through training on the principles of good clinical practice (GCP), as defined by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), adopted by regulatory authorities in the United States, Japan and the European Union. Although these GCP principles provide an important foundation for promoting the conduct of quality clinical trials, the industry standard "one-size-fits-all" GCP training may not fully prepare investigators and delegates for conducting quality clinical trials. Routine GCP training alone may not be sufficient to prepare an inexperienced member of a site team, while repeating such training is unlikely to enhance the qualifications of an experienced researcher. The CTTI project team used findings from qualitative research activities, as well as input from an expert meeting with multiple stakeholders, to identify gaps and redundancies in the current training of investigators and their delegates and recommend practical, action-based solutions. CTTI provides recommendations on how to implement a more efficient and effective means of preparedness and qualification of investigators and delegates, determining whether a site team is a good fit for a particular protocol, and improving the quality of clinical trial conduct.

16 February 2018 in Clinical Trials
Verified
Journal Article
Open access
ACAmy Corneli
Amy Corneli
ZHZachary Hallinan
Zachary Hallinan
GHGerrit Hamre
Gerrit Hamre
BPBrian Perry
Brian Perry
JGJennifer C Goldsack
Jennifer C Goldsack
AFAnnemarie Forrest
Annemarie Forrest
The mission of the Clinical Trials Transformation Initiative, a public–private partnership co-founded by the U.S. Food and Drug Administration and Duke University, is to develop and drive adoption of practices that will increase the quality and efficiency of clinical trials. The Clinical Trials Transformation Initiative works collaboratively with key stakeholders, implements “fit-for-purpose” evidence-gathering projects, and develops actionable recommendations and tools to address the challenges faced by the clinical trials enterprise. In pursuit of its mission, The Clinical Trials Transformation Initiative follows an innovative and collaborative, five-step methodology: (1) state the problem and identify impediments to research, (2) gather evidence to identify gaps and barriers, (3) explore results by analyzing and interpreting findings, (4) finalize solutions by developing recommendations and tools, and (5) drive adoption through disseminating and implementing recommendations and tools. This article describes each step of the Clinical Trials Transformation Initiative's methodology, with a specific focus on describing the evidence-gathering activities.

15 December 2016 in JMIR Cancer
Verified
Journal Article
Open access
RPRaymond P Perez
Raymond P Perez
SFShanda Finnigan
Shanda Finnigan
KPKrupa Patel
Krupa Patel
SWShanell Whitney
Shanell Whitney
AFAnnemarie Forrest
Annemarie Forrest
Patient-Centered Innovations, Education and Technology for Cancer Care and Cancer Research